- Home
- Products
Inqovi (decitabine and cedazuridine)
Inqovi (decitabine and cedazuridine)
- Medicine Name: Inqovi
- Generic Name: Decitabine and Cedazuridine
- Dosage Form & Strength: Tablets – 35 mg Decitabine and 100 mg Cedazuridine
- Manufactured By: Astex Pharmaceuticals, Inc.
Inqovi is a combination oral therapy that includes decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor. It is used for the treatment of adult patients with:
- Previously treated and untreated myelodysplastic syndromes (MDS)
- De novo and secondary MDS, including French-American-British (FAB) classification subtypes
- Intermediate-1, Intermediate-2, and High-Risk groups based on the International Prognostic Scoring System (IPSS)
Recommended Dosage:
Take 1 tablet orally once daily on an empty stomach for the first 5 days of each 28-day cycle.
- Swallow the tablet whole at approximately the same time each day
- Do not eat for at least 2 hours before or after taking the tablet
- If a dose is missed by more than 12 hours, skip the dose and extend the treatment cycle by 1 day
Do not substitute Inqovi tablets for IV decitabine within the same treatment cycle
Consider antiemetics prior to dosing to manage nausea or vomiting
Perform complete blood counts before initiating treatment, before each cycle, and as clinically indicated
Fetal harm may occur if administered during pregnancy. Verify pregnancy status before starting therapy
Women should not breastfeed during treatment and for at least 2 weeks following the final dose
Due to genotoxicity, male patients with reproductive potential partners should use contraception during and for 3 months after the last dose
To import Inqovi (Decitabine and Cedazuridine) via GlobalRareMeds, the following documents are required:
- Valid prescription from a qualified oncologist
- Diagnostic reports indicating the patient’s condition
- Government-issued photo ID of the patient
Order Confirmation:
Orders will only be confirmed after the verification of documentation. An import permit may be required based on local laws.
GlobalRareMeds sources Inqovi tablets through authorized and globally certified suppliers from the USA, Canada, Europe, and Australia.
All orders are processed through our fulfillment center in Ambernath, Thane District, and delivered securely after pharmacist verification.
We offer delivery across:
- India – Including cities like Mumbai, Delhi, Chennai, Bangalore, Hyderabad, Kolkata, Ahmedabad, Pune, and others
- Global destinations – Subject to compliance with local regulations
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name for Inqovi?
A. The generic name is Decitabine and Cedazuridine.
Q. Who manufactures Inqovi?
A. Inqovi is manufactured by Astex Pharmaceuticals, Inc.
Q. Is Inqovi FDA approved?
A. Yes, Inqovi was approved by the FDA on July 7, 2020.
Q. What is Inqovi used for?
A. Inqovi is used to treat adult patients with MDS (myelodysplastic syndromes), both de novo and secondary, including intermediate-1, intermediate-2, and high-risk IPSS classifications.
Q. How is Inqovi supplied?
A. Inqovi is supplied as oral tablets containing 35 mg of Decitabine and 100 mg of Cedazuridine.
Q. What are the common side effects of Inqovi?
A. Common side effects include fatigue, nausea, rash, diarrhea, febrile neutropenia, mucositis, constipation, myalgia, dizziness, pneumonia, and transaminase elevation.
Q. How should Inqovi be stored?
A. Store at 20°C to 25°C (68°F to 77°F). Keep the tablets in their original blister packaging and protect from moisture.
Q. Can Inqovi be taken during pregnancy or breastfeeding?
A. No. Inqovi may cause fetal harm and is not recommended during pregnancy or breastfeeding. Contraception is advised during treatment.
Q. How can I get Inqovi in India?
A. Submit a valid prescription and documentation to GlobalRareMeds. We ensure secure and compliant access to the medicine.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
